Drug Discovery & Development
Top 10 ScienceBoard stories for 2020
For many of us, 2020 did not pan out as planned. The emergence of the COVID-19 pandemic has drastically changed our daily lives. Here at ScienceBoard.net, we have provided timely and evidence-based information to our readers regarding COVID-19, as well as many other topics in the biopharmaceutical and life sciences industries.  Discuss
FDA issues EUA for Moderna COVID-19 vaccine
Just one day after a favorable committee recommendation, the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the messenger RNA (mRNA) COVID-19 vaccine from Moderna. The company's mRNA-1273 vaccine now becomes the second COVID-19 vaccine on the U.S. market, after a vaccine from Pfizer and BioNTech was granted an EUA last week.  Discuss
New discovery could lead to broad-spectrum antivirals
Scientists have identified a key human gene that is required for cells to consume and destroy viruses. The results of the study were published in Nature on December 16 and could point to new treatments to target viral infections, including COVID-19.  Discuss
FDA committee votes favorably for Moderna COVID-19 vaccine EUA
Moderna's messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273, received a favorable recommendation on December 17 from an advisory committee to the U.S. Food and Drug Administration (FDA). The committee's OK means that mRNA-1273 will probably receive an emergency use authorization (EUA) within days.  Discuss
New immunotherapy piggybacks off polio vaccine to treat cancer
As if we needed another reason to get vaccinated, researchers have developed a technology that leverages the polio vaccine to help treat cancer for those who develop the disease later in life. The technology, conceived at Duke University and developed by Istari Oncology, uses antigens produced by the polio vaccine to trigger the immune system to eat away at targeted cancer cells.  Discuss
Moderna's vaccine data support high efficacy, safety prior to FDA meeting
Moderna has published information supporting a 94.1% efficacy rate for its messenger RNA (mRNA) COVID-19 vaccine, mRNA-1273. The company made the data available ahead of a December 17 committee meeting at the U.S. Food and Drug Administration (FDA) to review the vaccine candidate.  Discuss
Genes provide new targets for COVID-19 therapies
Genes associated with antiviral immunity and lung inflammation have been tied to severe cases of COVID-19 in a new genome-wide analysis conducted in the U.K. The results, published in Nature on December 11, reveal new therapeutic targets for drug repurposing and development efforts.  Discuss
Global health R&D stalls as resources are redirected to COVID-19
The current coronavirus pandemic has set back progress in research and development (R&D) on neglected diseases and other long-standing global health challenges by disrupting ongoing research and redirecting resources to COVID-19 work, according to a new report released on December 11 by the nonprofit Global Health Technologies Coalition.  Discuss
FDA issues EUA for Pfizer, BioNTech COVID-19 vaccine
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. The move comes after the FDA's Vaccines and Related Biological Products Advisory Committee issued a positive recommendation for the vaccine.
FDA committee gives nod to move Pfizer, BioNTech COVID-19 vaccine toward EUA
A COVID-19 vaccine candidate from Pfizer-BioNTech, BNT162b2, passed a major milestone today when a U.S. Food and Drug Administration (FDA) advisory committee determined that the benefits of the candidate in preventing COVID-19 outweigh its risks. The advice of the committee will likely lead to the issuance of an emergency use authorization (EUA) for the vaccine by the FDA within days.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter